TC Biopharm (Holdings) Plc (TCBP)
| Market Cap | 320.02K |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -14.63M |
| Shares Out | 548.07K |
| EPS (ttm) | -78.81 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 185,576 |
| Open | 0.609 |
| Previous Close | 0.585 |
| Day's Range | 0.581 - 0.609 |
| 52-Week Range | 0.436 - 41.500 |
| Beta | 0.02 |
| Analysts | Strong Buy |
| Price Target | 3.00 (+413.79%) |
| Earnings Date | Feb 9, 2025 |
About TCBP
TC Biopharm (Holdings) Plc, a clinical-stage biopharmaceutical company, focuses on the development of immunotherapy products based on its allogeneic gamma delta T cell platform. Its product pipeline includes OmnImmune, an allogeneic unmodified gamma-delta T cell therapy product under Phase 2/3 trails for the treatment of acute myeloid leukemia; and ImmuniStim, an unmodified cell therapy to treat viral infections as well as cancers. The company was founded in 2013 and is headquartered in Motherwell, the United Kingdom. [Read more]
Analyst Forecast
According to one analyst, the rating for TCBP stock is "Strong Buy" and the 12-month stock price forecast is $3.0.
News
TCBP Partners with CareDx to Support ACHIEVE Clinical Trial Using AlloCell for Pharmacokinetic Monitoring of Allogeneic Cell Therapy
EDINBURGH, Scotland , Dec. 11, 2024 /PRNewswire/ -- TC BioPharm (Holdings) PLC ("TC BioPharm" or the "Company") (NASDAQ: TCBP) a clinical-stage biotechnology company developing platform allogeneic gam...
TCBP Provides Quarterly Update on the ACHIEVE (UK) Clinical Trial
Positive safety data, allowing for exploration of higher TCB008 doses 4 UK-based clinical sites recruiting patients, with a further 2 sites expected in H1 2025 EDINBURGH, Scotland , Dec. 4, 2024 /PRNe...
TCBP Awarded Non-Dilutive Funding, ScaleReady's G-Rex® Grant
EDINBURGH, Scotland , Nov. 12, 2024 /PRNewswire/ -- TC BioPharm (Holdings) PLC ("TC BioPharm" or the "Company") (NASDAQ: TCBP), a clinical-stage biotechnology company developing platform allogeneic ga...
TCBP Provides Shareholder Update and Highlights Recent Milestone Achievements
EDINBURGH, Scotland , Oct. 30, 2024 /PRNewswire/ -- TC BioPharm (Holdings) PLC ("TC BioPharm" or the "Company") (NASDAQ: TCBP), a clinical-stage biotechnology company developing platform allogeneic ga...
TCBP Responds to False Social Media Claim
TC BioPharm remains compliant with all Nasdaq listing requirements and will continue trading on the exchange EDINBURGH, Scotland , Oct. 25, 2024 /PRNewswire/ -- TC BioPharm (Holdings) PLC ("TC BioPhar...
TCBP Enters Research Planning Collaboration with Dr. Carlos Maluquer de Motes for Mpox Therapeutic
EDINBURGH, Scotland , Oct. 22, 2024 /PRNewswire/ -- TC BioPharm (Holdings) PLC ("TC BioPharm" or the "Company") (NASDAQ: TCBP), a clinical-stage biotechnology company developing platform allogeneic ga...
TCBP Announces Artificial Intelligence Initiative with Partner Carnegie Mellon University for Donor Screening
TC BioPharm Limited is partnering with Dr. Wei Wu of Carnegie Mellon University to create an artificial intelligence solution to optimize the donor screening and matching process The software could ha...
TCBP Announces Site Opening of Guys and St. Thomas Hospital
Additional London-based clinic to increase enrolment velocity Leading hospital with extensive cell therapy and oncology trial experience EDINBURGH, Scotland , Sept. 25, 2024 /PRNewswire/ -- TC BioPhar...
TCBP to Present at the 2024 ThinkEquity Conference in NYC
EDINBURGH, Scotland , Sept. 24, 2024 /PRNewswire/ -- TC BioPharm (Holdings) PLC ("TC BioPharm" or the "Company") (NASDAQ: TCBP) a clinical-stage biotechnology company developing platform allogeneic ga...
TCBP Announces First Patient Completed the Full Fose Regimen in ACHIEVE Clinical Trial
No TCB008-related Adverse Events seen in any of the re-start patients 6 Patients received second dose, 3 Patients received third dose, 1 Patient received fourth dose EDINBURGH, Scotland, Sept. 12, 202...
TC BioPharm Intends to Launch Preclinical Studies for Treatment of Monkey Pox
EDINBURGH, Scotland , Sept. 9, 2024 /PRNewswire/ -- TC BioPharm (Holdings) PLC ("TC BioPharm" or the "Company") (NASDAQ: TCBP) a clinical stage biotechnology company developing platform allogeneic ga...
TCBP Announces Participation at the H.C. Wainwright 26th Annual Global Investment Conference
EDINBURGH, Scotland , Sept. 5, 2024 /PRNewswire/ -- TC BioPharm (Holdings) PLC ("TC BioPharm" or the "Company") (NASDAQ: TCBP) a clinical stage biotechnology company developing platform allogeneic gam...
TCBP Announces Dosing of 5 New Patients in ACHIEVE
5 New patients dosed, bringing total to 6 patients dosed in ACHIEVE at higher dose level 5 Patients received second dose 2 Patients received third dose EDINBURGH, Scotland , Sept. 3, 2024 /PRNewswire/...
TC BioPharm Announces Closing of Upsized $6.0 Million Public Offering
EDINBURGH, Scotland , Aug. 28, 2024 /PRNewswire/ -- TC BioPharm (Holdings) PLC ("TC BioPharm" or the "Company") (NASDAQ: TCBP) a clinical stage biotechnology company developing platform allogeneic gam...
TC BioPharm Announces Grant of European Patent Covering Use of Modified Gamma Delta Cells for the Treatment of Cancer and Viral Indications
EDINBURGH, Scotland , Aug. 28, 2024 /PRNewswire/ -- TC BioPharm (Holdings) PLC ("TC BioPharm" or the "Company") (NASDAQ: TCBP) a clinical stage biotechnology company developing platform allogeneic gam...
TC BioPharm Regains Compliance with Nasdaq Listing Rule 5550(b)
EDINBURGH, Scotland , Aug. 15, 2024 /PRNewswire/ -- TC BioPharm (Holdings) PLC ("TC BioPharm" or the "Company") (NASDAQ: TCBP) a clinical stage biotechnology company developing platform allogeneic gam...
TC BioPharm Announces Closing of $2.0 Million Public Offering
EDINBURGH, Scotland , Aug. 15, 2024 /PRNewswire/ -- TC BioPharm (Holdings) PLC ("TC BioPharm" or the "Company") (NASDAQ: TCBP) a clinical stage biotechnology company developing platform allogeneic gam...
TC BioPharm Announces Pricing of $2.0 Registered Direct Offering
EDINBURGH, Scotland , Aug. 13, 2024 /PRNewswire/ -- TC BioPharm (Holdings) PLC ("TC BioPharm" or the "Company") (NASDAQ: TCBP) a clinical stage biotechnology company developing platform allogeneic gam...
TCBP Announces Plan to Implement ADS Ratio Change
EDINBURGH, Scotland , July 31, 2024 /PRNewswire/ -- TC BioPharm (Holdings) PLC ("TC BioPharm" or the "Company") (NASDAQ: TCBP) a clinical stage biotechnology company developing platform allogeneic gam...
TCBP Announces Dosing of 6th Patient in ACHIEVE Study in Patients with Acute Myeloid Leukemia
5 patients treated in "safety cohort" showed no drug related Serious Adverse Events Restart of trial after amendment approved by MHRA to increase dose level EDINBURGH, Scotland , July 22, 2024 /PRNews...
TCBP Announces Launch of Compassionate Use Program for TCB008
The Company's lead therapeutic will be available through a newly opened compassionate use program EDINBURGH, Scotland , May 15, 2024 /PRNewswire/ -- TC BioPharm (Holdings) PLC ("TC BioPharm" or the "C...
TC BioPharm Announces Exercise of Warrants for £3.1 Million Gross Proceeds
EDINBURGH, Scotland , May 6, 2024 /PRNewswire/ -- TC BioPharm (Holdings) plc ("TC BioPharm" or the "Company") (NASDAQ: TCBP), a clinical stage biotechnology company developing platform allogeneic gamm...
TC BioPharm Announces Execution of Second Non-Binding Letter of Intent for Acquisition, Targeting Innovative CAR-T Therapies
Acquisition target has established proof of concept data demonstrating the therapeutic potential for the treatment of multiple solid tumors EDINBURGH, Scotland , May 6, 2024 /PRNewswire/ -- TC BioPha...
TCBP Announces Execution of Non-Binding Letter of Intent for Acquisition of NK Platform Technologies
EDINBURGH, Scotland , April 4, 2024 /PRNewswire/ -- TC BioPharm (Holdings) PLC ("TC BioPharm" or the "Company") (NASDAQ: TCBP) a clinical stage biotechnology company developing platform allogeneic gam...
TCBP Increasing Treatment Capacity with Expanded Manufacturing Process
Developing streamlined approach to reduce cost per patient by 85% EDINBURGH, Scotland , April 2, 2024 /PRNewswire/ -- TC BioPharm (Holdings) PLC ("TC BioPharm" or the "Company") (NASDAQ: TCBP) a clini...